Skip to main content

Treace Publishes Inaugural ESG Report

Written by Customer Service on . Posted in Public Companies.

PONTE VEDRA, Fla., April 04, 2023 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today published its inaugural Environmental, Social and Governance (ESG) report.

This report highlights the Company’s strategic and ESG-related initiatives from the past year, including:

  • Advancing the Company’s mission to improve surgical outcomes for bunion patients;
  • Formally delegating responsibility to oversee ESG initiatives to the Nominating, Compliance and Governance Committee of the Company’s Board of Directors, and changing the committee’s name to the Nominating, Compliance & ESG Committee;
  • Revamping and relaunching the Company’s Code of Conduct for employees and directors centered around our four core values;
  • Introducing a Supplier Code of Conduct to better communicate expectations around ethical and responsible business conduct by the Company’s suppliers; and
  • Moving into a new headquarters that provides additional capacity for the Company’s growing business along with environmentally-friendly features.

“We are pleased to issue our inaugural ESG report which highlights our commitment to improve the lives of bunion patients and operate our business responsibly. We recognize the importance of ESG to our stakeholders, internal and external, and will continue to integrate ESG considerations into the ways we manage our business,” said John T. Treace, CEO, Founder, and Board Member.

In developing this report, Treace has prioritized ESG issues applicable to its industry and its business. The Company’s analysis was informed by feedback from investors and other stakeholders, peer benchmarking, analysis prepared by ESG rating agencies, and guidance from leading ESG reporting frameworks such as the Sustainability Accounting Standards Board (SASB). The Company’s disclosures in this report incorporate SASB standards and metrics for the Medical Equipment & Supplies industry. An index containing SASB-aligned disclosures is available in the appendix of the report. Please visit the Investor Relations section of the Company’s website to view Treace’s 2023 ESG Report.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:

Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:

Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.